Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 18Melanoma 13Neoplasms 5Head and Neck Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Lung Neoplasms 4Stomach Neoplasms 3Neoplasm Metastasis 2Kidney Neoplasms 2Gastrointestinal Neoplasms 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Hepatocellular 2Thyroid Neoplasms 1Skin Neoplasms 1Sexual Dysfunction, Physiological 1Sarcopenia 1Recurrent Squamous Cell Lung Carcinoma 1Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Oropharyngeal Neoplasms 1Neoplasms, Squamous Cell 1Motor Activity 1Lung Squamous Cell Carcinoma Stage IV 1Locally Advanced Melanoma 1Locally Advanced Gastric Cancer 1Liver Diseases 1Hereditary Sensory and Autonomic Neuropathies 1Eunuchism 1Esophageal Neoplasms 1Erectile Dysfunction 1

Interventions

Blood Specimen Collection 2toripalimab 1tislelizumab 1sintilimab 1pembrolizumab 1lenvatinib 1gadolinium ethoxybenzyl DTPA 1camrelizumab 1User-Centered Design 1Standard of Care 1Shadowing Technique, Histology 1Nivolumab 1Neuropsychological Tests 1Lead 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Liver Diseases × Nivolumab × Clear all
NCT04627012 2024-03-06

Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma

Sun Yat-sen University

Completed
600 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡